Imatinate 400mg Capsule (Imatinib)

Imatinate 400mg Capsule is a prescription medicine containing Imatinib. It is belongs to the tyrosine kinase inhibitor targeting bcr::abl1, kit and pdgfr class. The medicine should be used only under the supervision of a clinician experienced in the relevant disease area.
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), with dose and treatment strategy depending on disease phase and response. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in defined settings.
Imatinib 400mg capsule inhibits several abnormal or overactive tyrosine kinases, most importantly BCR::ABL1, KIT and PDGFR. By blocking the kinase that drives a susceptible malignancy, imatinib capsule reduces proliferative signalling and promotes disease control. Its mechanism makes biomarker/disease context essential. The 400mg strength describes the commercial presentation; it does not automatically represent the complete prescribed dose. However, the dose and duration depend on diagnosis, treatment protocol, organ function, concomitant medicines and treatment tolerance.

Imatinate 400mg capsule may be prescribed in the following established clinical settings. The exact treatment line, combination regimen and duration depend on the diagnosis, current labeling and specialist assessment.

Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), with dose and treatment strategy depending on disease phase and response.
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in defined settings.
PDGFR-rearranged MDS/MPD, selected systemic mastocytosis, hypereosinophilic syndrome/chronic eosinophilic leukemia, KIT-positive gastrointestinal stromal tumour (GIST), and dermatofibrosarcoma protuberans (DFSP) according to biomarker status and applicable labeling.

Imatinib capsule inhibits several abnormal or overactive tyrosine kinases, most importantly BCR::ABL1, KIT and PDGFR. By blocking the kinase that drives a susceptible malignancy, the medicine reduces proliferative signalling and promotes disease control. Its mechanism makes biomarker/disease context essential.

• The clinical evidence referenced here based on imatinib 400mg capsules and the treatment regimens in which they are administered, and not the Imatinate capsule commercial product specifically.
  
• The use of imatinib 400mg has led to tremendous improvements in the management of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) and contributed in making targeted kinase inhibitors a valuable cancer treatment modality.
  
• Imatinib 400mg is also backed by extensive clinical evidence for the treatment of KIT-positive gastrointestinal stromal tumors (GIST) as well as other rare diseases characterized by certain molecular anomalies.
  
• The evidence available varies based on the disease and regimen used and pertains to imatinib 400mg as a drug and not as clinical trial evidence for the Imatinate 400mg commercial product specifically.
  
  

The side effects of Imatinib 400mg capsule vary by indication, dose, treatment duration, concomitant medicines and individual patient factors. Common or clinically relevant effects include:

• Edema/fluid retention
  
• Nausea
  
• Muscle cramps
  
• Musculoskeletal pain
  
• Diarrhea
  
• Rash
  
• Fatigue
  
• Myelosuppression
  
• Liver-enzyme elevations

Serious or persistent symptoms should be assessed promptly. The treating team should provide medicine-specific instructions on which symptoms require urgent medical attention.

The dose of Imatinate capsule depends on the indication and clinical setting. The 400mg presentation should not be confused with the total prescribed daily dose.

These are molecule-level examples from regulatory labeling or established product information and are not instructions for self-dosing. The treating specialist determines the actual dose, schedule, dose modifications and supportive medicines.

If a dose of Imatinate 400mg capsule is missed, follow the current patient leaflet and the treating team's instructions. Do not automatically double the next dose. If vomiting occurs after an oral dose, do not repeat the dose unless specifically instructed.

Monitoring is individualized according to the disease and treatment regimen. It may include:

• CBC
  
• Liver function
  
• Renal function
  
• Weight and edema
  
• BCR::ABL1 molecular response in CML
  
• Disease-specific imaging/biomarkers in GIST and other indications
  
• Cardiac status in susceptible patients
  

1. DailyMed. Imatinib Mesylate Tablets prescribing information, updated September 2026 https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a819a954-41c9-4d49-a74e-c8c4b338b22a&version=3​
2. Current CML/GIST and disease-specific oncology guidelines https://pmc.ncbi.nlm.nih.gov/articles/PMC12529753/​
3. Current India-specific Imatinate package insert, including confirmation of capsule versus tablet presentation, before publication https://www.researchgate.net/publication/280402583_Formulation_and_evaluation_of_floating_controlled_release_tablets_of_Imatinib_mesylate_using_hydrophilic_matrix_system​
4. European LeukemiaNet. 2025 European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia.Leukemia. 2025;39:1797–1813 https://pubmed.ncbi.nlm.nih.gov/40646132/​
5. U.S. Food and Drug Administration. GLEEVEC (imatinib mesylate) Tablets Prescribing Information. Updated July 2026 https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021588s067lbl.pdf​